Allen Mooney & Barnes Investment Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.6M Sell
81,986
-6,063
-7% -$1.3M 3.14% 3
2026
Q1
$19.1M Buy
88,049
+953
+1% +$211K 2.75% 5
2025
Q4
$19.9M Buy
87,096
+811
+0.9% +$185K 2.99% 6
2025
Q3
$20M Buy
86,285
+793
+0.9% +$161K 3.11% 4
2025
Q2
$15.9M Buy
85,492
+910
+1% +$169K 2.61% 10
2025
Q1
$17.7M Buy
84,582
+411
+0.5% +$79.9K 2.88% 6
2024
Q4
$15M Sell
84,171
-433
-0.5% -$79.6K 2.52% 10
2024
Q3
$16.7M Sell
84,604
-2,527
-3% -$472K 2.84% 9
2024
Q2
$14.9M Buy
87,131
+364
+0.4% +$60.3K 2.67% 8
2024
Q1
$14.5M Sell
86,767
-1,181
-1% -$204K 2.79% 8
2023
Q4
$13.6M Buy
87,948
+1,275
+1% +$186K 2.59% 9
2023
Q3
$12.9M Buy
86,673
+3,242
+4% +$476K 2.75% 6
2023
Q2
$11.2M Buy
83,431
+1,121
+1% +$164K 2.49% 10
2023
Q1
$13.1M Buy
82,310
+982
+1% +$150K 3.14% 6
2022
Q4
$13.1M Buy
81,328
+315
+0.4% +$48.3K 3.16% 3
2022
Q3
$10.9M Buy
81,013
+2,572
+3% +$369K 2.91% 6
2022
Q2
$12M Buy
78,441
+837
+1% +$128K 3.08% 4
2022
Q1
$12.6M Buy
+77,604
New +$11.3M 2.79% 5

Other funds holding ABBV

Allen Mooney & Barnes Investment Advisors's ABBV Position: Q2 2026 in Review

Allen Mooney & Barnes Investment Advisors reduced its AbbVie (ABBV) stake by 6.9% in Q2 2026, selling an estimated $1.3M and leaving 81,986 shares worth $20.6M. The position accounts for 3.14% of the portfolio, ranked #3.

Allen Mooney & Barnes Investment Advisors first reported a position in ABBV in Q1 2022 and has held it in 18 quarters since. 2,137 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Allen Mooney & Barnes Investment Advisors held 81,986 shares of AbbVie worth $20.6M as of Q2 2026.
  • Allen Mooney & Barnes Investment Advisors sold 6,063 AbbVie shares in Q2 2026, an estimated $1.3M.
  • AbbVie made up 3.14% of Allen Mooney & Barnes Investment Advisors's portfolio in Q2 2026, its #3 holding.
  • Allen Mooney & Barnes Investment Advisors first reported a position in AbbVie in Q1 2022 and has held it in 18 quarters since.
  • 2,137 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Allen Mooney & Barnes Investment Advisors's 13F filing for Q2 2026, filed 13 Jul 2026.